Open Access Full Text Article

Non-Invasive Prenatal Testing: Advances, Applications, and Limitations in Prenatal Screening

Ting Yu[1], Xiaona Xu[1], Qingzheng Wei[2,*]

ABSTRACT

Non-invasive prenatal testing (NIPT) is a prenatal screening technology based on the analysis of cell-free fetal DNA (cfDNA) detected in maternal peripheral blood. It offers high detection efficiency for common chromosomal aneuploidies, such as trisomy 21 (T21), trisomy 18 (T18), trisomy 13 (T13), and sex chromosome aneuploidies (SCA). Additionally, NIPT has expanded to include the screening of subchromosomal microdeletions and microduplications, single-gene genetic diseases, and has even demonstrated certain diagnostic value for placental-derived complications during pregnancy. However, some of the problems it presents, such as technical limitations and ethical or psychological issues, cannot be overlooked. This article reviews the advancements and limitations of NIPT in prenatal screening.

Key words: Cell-free fetal DNA, High-throughput sequencing, Non-invasive prenatal testing, Prenatal screening

[1]*Central Laboratory, Qingdao Municipal Hospital, Qingdao, Shandong, China*

[2]*Clinical Laboratory, Qingdao Municipal Hospital, Qingdao, Shandong, China*

Correspondence

Qingzheng Wei, Clinical Laboratory, Qingdao Municipal Hospital, Qingdao, Shandong, China

Email: 1270700065@qq.com

Check for updates

BioMedPress
The Open Access Publisher

INTRODUCTION

Since the 1980s, prenatal testing has significantly contributed to reducing congenital disabilities and improving population health. Traditional prenatal screening techniques include ultrasound examination, serological screening, and chromosome karyotype analysis. Nonetheless, these approaches have notable limitations: ultrasound is limited by weak penetration and image distortion, leading to misdiagnosis or missed cases; serological screening has relatively low accuracy; and invasive procedures like amniocentesis and cord blood puncture carry risks of intrauterine infection and miscarriage.

In recent years, high-throughput sequencing based on cell-free DNA (cfDNA), also referred to as non-invasive prenatal testing (NIPT), has emerged as a powerful tool for detecting fetal chromosomal aneuploidy and has gradually become an essential component of prenatal screening. Moreover, advances in NIPT have expanded its applications to include prenatal screening of subchromosomal microdeletions and microduplications, single-gene genetic diseases, and pregnancy complications.

However, any emerging technology inevitably introduces some negative consequences. Therefore, this article summarizes the advancements in prenatal screening and analyzes the limitations of NIPT, as well as the associated ethical and psychological implications for pregnant women.

SOURCE AND DETECTION PRINCIPLE OF CFDNA IN MATERNAL PERIPHERAL BLOOD

As early as 1997, Lo *et al.*[1] detected fetal Y chromosome DNA in maternal peripheral blood, confirming the existence of cell-free DNA (cfDNA) and establishing the theoretical foundation for non-invasive prenatal testing (NIPT). Subsequent studies revealed that cfDNA concentration in maternal peripheral blood increases with gestational age and can be detected as early as the 7th week of pregnancy[2]. CfDNA is primarily derived from placental trophoblasts and maternal hematopoietic cells[3–5], consisting of small fragments approximately 100–200 base pairs in length, which account for 5%–30% of the total cfDNA in maternal blood. After childbirth, cfDNA rapidly degrades, becoming undetectable within 2 hours, with an average half-life of 16.3 minutes[6–8]. For a long time, the low concentration of fetal cfDNA and high background noise from maternal DNA hindered its application in prenatal screening. However, with the advancement of next-generation sequencing (NGS), this limitation has been overcome. NGS offers high throughput, enabling large-scale genomic sequencing. This technology can simultaneously analyze hundreds of thousands to millions of DNA sequences, allowing for whole-genome sequencing of samples. By quan-

tifying changes in the number of these DNA fragments, bioinformatics analysis can detect fetal chromosomal abnormalities. Due to its efficacy and accuracy, NGS-based cfDNA analysis has been adopted for clinical prenatal testing.

CLINICAL APPLICATION OF NIPT

Detection of Fetal T21, T18, T13, and SCA

Non-invasive prenatal testing (NIPT) is highly sensitive and specific for detecting aneuploidies in singleton fetuses on chromosomes 21, 18, and 13. A meta-analysis by Gil MM et al.[9] of over 200,000 pregnant women with singleton fetuses found that NIPT had detection rates of 99.7% for T21, 97.9% for T18, and 99.7% for T13, with false-positive rates of 0.04% for each. However, current reports on NIPT's accuracy vary. Some studies report a positive predictive value (PPV) of 83% to 92.9% for NIPT in detecting sex chromosome aneuploidies (SCA) in singleton pregnancies[10–12], while others report a PPV as low as 53.1%[13].

Additionally, with the rising incidence of infertility, the number of twin or multiple pregnancies resulting from assisted reproductive technology has increased annually. Studies have evaluated NIPT's accuracy in detecting chromosomal abnormalities in twins, showing that cell-free DNA (cfDNA) testing for T21, T18, and T13 in twin pregnancies yields results comparable to those in singleton pregnancies[14–16]. However, the limited number of SCA cases in these studies precludes an accurate assessment of cfDNA's predictive value for these anomalies.

Detection of Autosomal Abnormalities and Subchromosomal Microdeletions/Microduplications

With the continuous development of sequencing technologies and advances in clinical settings, international and domestic consensus guidelines have expanded the applications of non-invasive prenatal testing (NIPT). These now include screening for additional chromosomal numerical abnormalities and microdeletion/microduplication syndromes. In published studies, researchers found that a high-risk NIPT result for chromosomes 2, 9, and 22 could be confirmed as fetal trisomy or mosaic trisomy through follow-up tests such as fluorescence in situ hybridization (FISH) and DNA microarray[17–19]. Although NIPT has demonstrated potential for detecting other autosomal abnormalities, its application to all chromosomes remains controversial due to

ethical concerns, increased psychological burden on pregnant women, and the potential for unnecessary invasive diagnostic procedures.

Microdeletion/microduplication syndromes, caused by chromosomal copy number variations (CNVs), are characterized by complex phenotypes and account for 1–2% of congenital malformations in neonates. The accuracy of NIPT for these conditions depends on factors such as: the proportion of cell-free DNA (cfDNA) in maternal plasma, the size of the fetal microdeletion/microduplication, sequencing coverage, and bioinformatics analysis methods[20,21].

NIPT-plus, an advanced version of NIPT, improves the detection rate of microdeletion/microduplication syndromes by increasing sequencing depth and refining algorithms—without altering clinical procedures, requiring additional blood samples, or extending reporting time[22]. For example, a study by Xue et al.[23] reported that NIPT-plus achieved an 80% positive predictive value (PPV) for 22q11.2 microduplication syndrome, with PPVs of 75% for DiGeorge syndrome, and 50% for both Prader-Willi/Angelman syndrome and Cri-du-chat syndrome.

Currently, NIPT screening for common trisomies and sex chromosome aneuploidies (SCA) is widely accepted among pregnant women. However, its use for microdeletion/microduplication syndromes remains debated. Opponents argue that the relatively low PPV, high false-positive rate, and uncertain clinical significance of some CNVs create challenges in managing high-risk results. Proponents, however, emphasize that the primary goal of prenatal screening is to reduce the burden of fetal chromosomal abnormalities at birth. Thus, they advocate for including even low-PPV microdeletions/microduplications in screening programs.

Detection of Monogenic Diseases

Single-gene inherited diseases are a significant cause of congenital disabilities, resulting from pathogenic variants in a single gene and affecting approximately 1% of neonates[24]. Although each individual monogenic disease is rare, collectively, they are prevalent, with over 6,000 distinct disorders of known pathogenesis identified. Their combined incidence is similar to that of chromosomal disorders, with dominant conditions representing more than half of cases[25]. Affected children often present with severe symptoms and have limited treatment options. Furthermore, since many cases arise from de novo mutations, these children frequently lack a family history

of the disease, and their parents usually exhibit normal phenotypes. This makes prenatal diagnosis particularly challenging and often leads to underdetection.

Numerous studies have reported the use of non-invasive prenatal testing (NIPT) for single-gene disorders, including thalassemia, phenylketonuria, and Duchenne muscular dystrophy[26–28]. Notably, follow-up studies with invasive diagnostic confirmation have demonstrated strong concordance between NIPT and traditional diagnostic methods. In 2022, a study by Baylor College of Medicine screened over 2,000 individuals for 25 dominant monogenic diseases (involving 30 genes) and reported a positive detection rate of 5.7%, highlighting the clinical utility of NIPT for dominant monogenic disorders[29]. However, NIPT for fetal single-gene diseases has not yet been widely adopted in clinical practice due to high costs, lengthy turnaround times, and complex bioinformatic analysis.

Prenatal screening for pregnancy complications

Common complications during pregnancy include gestational diabetes mellitus (GDM), intrahepatic cholestasis of pregnancy (ICP), and preeclampsia. These conditions are highly prevalent, yet reliable methods for their early diagnosis remain lacking. Since cell-free DNA (cfDNA) is primarily derived from the placenta—the origin of many pregnancy complications—researchers have explored the potential of cfDNA fragment analysis for molecular detection. This approach has demonstrated promise not only for predicting fetal chromosomal abnormalities but also for assessing the risk of pregnancy complications in the mother.

GDM poses both short- and long-term risks to mothers and fetuses. Affected women face higher risks of polyhydramnios, metabolic disorders, and cesarean delivery, while their fetuses may experience macrosomia, growth restriction, and an elevated lifelong risk of diabetes and obesity. Bauer *et al.* found an association between elevated cfDNA levels and GDM, suggesting cfDNA's potential as a predictive marker[30].

ICP is characterized by severe pruritus, abnormal liver function, and elevated serum bile acids. This condition has a notable incidence during pregnancy and is associated with premature birth and intrauterine fetal death. A study of 831 pregnant women who received NIPT revealed that maternal cfDNA levels were significantly elevated in ICP cases compared to controls[31].

Preeclampsia presents with hypertension, edema, and proteinuria. Its pathogenesis involves reduced uterine-placental blood supply and/or increased fetal-placental demand, leading to a perfusion mismatch. This triggers the release of stress-related factors from the placenta and disrupts the balance between pro-angiogenic placental growth factor and anti-angiogenic soluble fms-like tyrosine kinase-1 (sFlt-1). Kumar *et al.* demonstrated that cfDNA levels are higher in preeclamptic women than in healthy controls[32]. Moreover, early-pregnancy whole-genome sequencing of plasma cfDNA combined with preeclampsia-associated promoter analysis achieved a prediction accuracy of 83%[33].

LIMITATIONS OF NIPT

Limitations of Technology and Clinical Applications

Non-invasive prenatal testing (NIPT) relies on short fragments of cell-free DNA (cfDNA) from the placenta in maternal peripheral blood, typically less than 200 bp in length. These fetal cfDNA signals may be diluted or obscured by maternal background DNA, increasing the risk of false-negative results for microdeletion/microduplication syndromes and monogenic diseases. The accuracy of NIPT is highly dependent on the fetal fraction (the proportion of fetal cfDNA in maternal blood). A low fetal fraction—due to early gestational age (<10 weeks) or maternal obesity (BMI $\geq$ 30)—increases the risk of false negatives[34].

Fetal cfDNA primarily originates from placental trophoblast cells. Discrepancies between the placental and fetal karyotypes (*e.g.*, confined placental mosaicism) can lead to false-positive or false-negative results[35]. Similarly, in twin pregnancies, an abnormal or "vanishing" twin may cause erroneous NIPT results[36]. Maternal chromosomal abnormalities—such as sex chromosome chimerism or microdeletions—may also be misattributed to the fetus, leading to false positives[37]. Additionally, malignant tumors in the mother can release tumor-derived DNA with chromosomal abnormalities, further increasing the risk of false positives[38].

Notably, NIPT cannot detect fetal structural abnormalities, such as neural tube defects or cardiac malformations; these still require ultrasound assessment.

Although NIPT is a screening tool, some patients mistakenly believe it can replace diagnostic tests like amniocentesis. Positive NIPT results must be confirmed through chorionic villus sampling (CVS) or

amniocentesis. However, CVS carries a risk of mis-diagnosis due to placental mosaicism. Furthermore, pregnancies involving embryo donation or surrogacy may complicate result interpretation due to genetic disparities between the mother and fetus. Finally, most NIPT algorithms are optimized for singleton pregnancies, and their accuracy in multiple gestations requires improvement [39].

Ethical and Psychological Challenges of NIPT

NIPT may lead to overtreatment, as false-positive results can prompt unnecessary invasive diagnostic procedures, increasing the risk of fetal loss. Conversely, false-negative results may result in medical disputes. Some medical institutions fail to adequately communicate the limitations of NIPT, leading patients to overestimate its accuracy and causing some pregnant women to mistakenly believe that NIPT can detect all birth defects. Furthermore, NIPT can determine fetal sex early, raising concerns about misuse in regions with a strong gender preference.

Beyond considering NIPT's accuracy, the psychological impact on pregnant women must not be overlooked [40]. Before testing, pregnant women should carefully weigh the benefits of early detection against potential risks, such as the stress of receiving positive results. High-risk results often trigger acute anxiety or depression, and the decision to undergo invasive procedures (*e.g.*, amniocentesis) may create a dilemma between miscarriage risks and reproductive choices. Additionally, deciding whether to continue a pregnancy upon diagnosing chromosomal abnormalities with mild phenotypes (*e.g.*, XXY, XXX, or XYY) or microdeletion/microduplication syndromes can cause conflicts between partners.

False positives not only pose physical risks through unnecessary invasive tests but may also undermine pregnant women's trust in the medical system. Conversely, false negatives—where an abnormality is unexpectedly discovered after delivery—may lead to anger or depression in families due to lack of prior warning.

CONCLUSIONS

Prenatal screening is particularly important because effective treatments for chromosomal diseases are currently lacking, and the risk of having a child with chromosomal abnormalities increases with maternal age, placing a significant burden on families and society. NIPT is a non-invasive, safe, and relatively painless test that has proven effective in detecting trisomy 21, trisomy 18, trisomy 13, and SCA, leading to widespread public acceptance. However, its application in detecting other chromosomal aneuploidies, fetal chromosome copy number variations, single-gene genetic disorders, and pregnancy complications remains in the exploratory stage, with significant limitations in technical principles, social ethics, and the psychological impact on pregnant women.

In the future, balancing the medical benefits and social risks of NIPT will require technological innovation, standardized management, and ethical guidelines to ensure precise and responsible clinical use.

ABBREVIATIONS

BMI (Body Mass Index) is a measure of body fat based on height and weight; **bp** (base pairs) are units of length for DNA fragments (e.g., 100–200 bp); **cfDNA** (cell-free DNA) refers to short DNA fragments circulating in the maternal bloodstream, primarily fetal DNA from the placenta in prenatal testing; **CNVs** (copy number variations) are gains or losses of DNA segments, which can result in microdeletions or microduplications; **CVS** (chorionic villus sampling) is an invasive prenatal diagnostic procedure that tests placental tissue for genetic abnormalities; **FISH** (fluorescence in situ hybridization) is a laboratory technique used to detect and localize specific DNA sequences on chromosomes; **GDM** (gestational diabetes mellitus) is a form of diabetes diagnosed during pregnancy; **ICP** (intrahepatic cholestasis of pregnancy) is a liver disorder in pregnancy, associated with severe itching and elevated bile acids; **NGS** (next-generation sequencing) is a high-throughput DNA sequencing technology enabling large-scale analysis, which underlies many NIPT workflows; **NIPT** (non-invasive prenatal testing) is a prenatal screening method analyzing cfDNA in maternal blood to detect chromosomal abnormalities in the fetus; **PPV** (positive predictive value) represents the likelihood that a positive test result correctly indicates the presence of a condition; **SCA** (sex chromosome aneuploidies) are abnormalities in the number of X or Y chromosomes (e.g., Turner syndrome [XO], Klinefelter syndrome [XXY]); **sFlt-1** (soluble fms-like tyrosine kinase-1) is an anti-angiogenic factor implicated in preeclampsia; **T13** (trisomy 13) refers to an extra copy of chromosome 13; **T18** (trisomy 18) is an extra copy of chromosome 18; and **T21** (trisomy 21) is an extra copy of chromosome 21 (Down syndrome).

ACKNOWLEDGMENTS

AUTHOR'S CONTRIBUTIONS

All authors contributed equally to the conception, literature review, and writing of this manuscript. All authors read and approved the final manuscript.

FUNDING

AVAILABILITY OF DATA AND MATERIALS

Not applicable.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES

1. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485–7. PMID: 9274585. Available from: https://doi.org/10.1016/S0140-6736(97)02174-0.

2. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. American Journal of Human Genetics. 1998;62(4):768–75. PMID: 9529358. Available from: https://doi.org/10.1086/301800.

3. Chim SS, Tong YK, Chiu RW, Lau TK, Leung TN, Chan LY. Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(41):14753–8. PMID: 16203989. Available from: https://doi.org/10.1073/pnas.0503335102.

4. Alberry M, Maddocks D, Jones M, Hadi MA, Abdel-Fattah S, Avent N. Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblast. Prenatal Diagnosis. 2007;27(5):415–8. PMID: 17286310. Available from: https://doi.org/10.1002/pd.1700.

5. Brison N, Neofytou M, Dehaspe L, Bayindir B, Bogaert KVD, Dardour L. Predicting fetoplacental chromosomal mosaicism during non-invasive prenatal testing. Prenatal Diagnosis. 2018;38(4):258–66. PMID: 29388226. Available from: https://doi.org/10.1002/pd.5223.

6. Goya R, Sun MG, Morin RD, Leung G, Ha G, Wiegand KC. SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics (Oxford, England). 2010;26(6):730–6. PMID: 20130035. Available from: https://doi.org/10.1093/bioinformatics/btq040.

7. Lo YM, Chan KC, Sun H, Chen EZ, Jiang P, Lun FM, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Science Translational Medicine. 2010;2(61):61ra91. PMID: 21148127. Available from: https://doi.org/10.1126/scitranslmed.3001720.

8. Chitty LS, Lo YM. Noninvasive Prenatal Screening for Genetic Diseases Using Massively Parallel Sequencing of Maternal Plasma DNA. Cold Spring Harbor Perspectives in Medicine. 2015;5(9):a023085. PMID: 26187875. Available from: https://doi.org/10.1101/cshperspect.a023085.

9. Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound in Obstetrics & Gynecology : The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2015;45(3):249–66. PMID: 25639627. Available from: https://doi.org/10.1002/uog.14791.

10. Mazloom AR, D, Oeth P, Wang H, Jensen T, Tynan J. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. Prenatal Diagnosis. 2013;33(6):591–7. PMID: 23592550. Available from: https://doi.org/10.1002/pd.4127.

11. Bianchi DW, Parsa S, Bhatt S, Halks-Miller M, Kurtzman K, Sehnert AJ. Fetal sex chromosome testing by maternal plasma DNA sequencing: clinical laboratory experience and biology. Obstetrics and Gynecology. 2015;125(2):375–82. PMID: 25568992. Available from: https://doi.org/10.1097/AOG.0000000000000637.

12. Nicolaides KH, Musci TJ, Struble CA, Syngelaki A, Gil MM. Assessment of fetal sex chromosome aneuploidy using directed cell-free DNA analysis. Fetal Diagnosis and Therapy. 2014;35(1):1–6. PMID: 24335155. Available from: https://doi.org/10.1159/000357198.

13. Suo F, Wang C, Liu T, Fang Y, Wu Q, Gu M. Noninvasive prenatal testing in detecting sex chromosome aneuploidy: A large-scale study in Xuzhou area of China. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2018;481:139–41. PMID: 29544746. Available from: https://doi.org/10.1016/j.cca.2018.03.007.

14. Meng M, Chen J, Yang Y, Zhang Y, Zou G, Zhou F, et al. The efficacy of expanded non-invasive prenatal testing (NIPT) in a high-risk twin pregnancies cohort. Acta Obstetricia et Gynecologica Scandinavica. 2024;103(12):2426–32. Available from: https://doi.org/10.1111/aogs.14958.

15. Wang D, Peng H, Wang Y, Hou Y, Guo F, Zhu J. Performance of noninvasive prenatal testing for twin pregnancies in South China. Journal of Assisted Reproduction and Genetics. 2023;40(9):2219–31. PMID: 37480419. Available from: https://doi.org/10.1007/s10815-023-02881-1.

16. Yuan X, Wang W, Dai L, Yong W, Pei C, Li J. Noninvasive prenatal testing, ultrasonographic findings and poor prenatal diagnosis rates for twin pregnancies: a retrospective study. BMC Pregnancy and Childbirth. 2023;23(1):351. PMID: 37179315. Available from: https://doi.org/10.1186/s12884-023-05642-1.

17. Ma J, Cram DS, Zhang J, Shang L, Yang H, Pan H. Birth of a child with trisomy 9 mosaicism syndrome associated with paternal isodisomy 9: case of a positive noninvasive prenatal test result unconfirmed by invasive prenatal diagnosis. Molecular Cytogenetics. 2015;8(1):44. PMID: 26120364. Available from: https://doi.org/10.1186/s13039-015-0145-4.

18. Song Y, Huang S, Zhou X, Jiang Y, Qi Q, Bian X, et al. Noninvasive prenatal testing for fetal aneuploidies in the first trimester of pregnancy. Ultrasound in Obstetrics & Gynecology : The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2015;45(1):55–60. PMID: 25044397. Available from: https://doi.org/10.1002/uog.13460.

19. Yu L, Fan Y, Hui Y, et al. Through 1 case of chromosome 22 chimeric discusses three body noninvasive prenatal detection of abnormal results follow-up diagnosis strategy. Chinese Journal of Laboratory Medicine. 2017;40(07):495. Available from: https://doi.org/10.3760/cma.j.issn.1009-9158.2017.07.005.

20. Yin AH, Peng CF, Zhao X, Caughey BA, Yang JX, Liu J. Noninvasive detection of fetal subchromosomal abnormalities by semiconductor sequencing of maternal plasma DNA. Proceedings of the National Academy of Sciences of the United States

of America. 2015;112(47):14670–5. PMID: 26554006. Available from: https://doi.org/10.1073/pnas.1518151112.

21. Zhao C, Tynan J, Ehrich M, Hannum G, McCullough R, Saldivar JS. Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. Clinical Chemistry. 2015;61(4):608–16. PMID: 25710461. Available from: https://doi.org/10.1373/clinchem.2014.233312.

22. Evans MI, Wapner RJ, Berkowitz RL. Noninvasive prenatal screening or advanced diagnostic testing: caveat emptor. American Journal of Obstetrics and Gynecology. 2016;215(3):298–305. PMID: 27131582. Available from: https://doi.org/10.1016/j.ajog.2016.04.029.

23. Huili X. Efficiency of expanded noninvasive prenatal testing in the detection of fetal subchromosomal microdeletion and microduplication in a cohort of 31,256 single pregnancies. Scientific Reports. 2022;12(1):19750. Available from: https://doi.org/10.1038/s41598-022-24337-9.

24. Chitty LS. Advances in the prenatal diagnosis of monogenic disorders. Prenatal Diagnosis. 2018;38(1):3–5. PMID: 29464795. Available from: https://doi.org/10.1002/pd.5208.

25. Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y. Molecular findings among patients referred for clinical whole-exome sequencing. Journal of the American Medical Association. 2014;312(18):1870–9. PMID: 25326635. Available from: https://doi.org/10.1001/jama.2014.14601.

26. Hudecova I, Chiu RW. Non-invasive prenatal diagnosis of thalassemias using maternal plasma cell free DNA. Best Practice {&}amp; Research Clinical Obstetrics {&}amp; Gynaecology. 2017;39:63–73. PMID: 27887921. Available from: https://doi.org/10.1016/j.bpobgyn.2016.10.016.

27. Duan H, Liu N, Zhao Z, et al. Non-invasive prenatal testing of pregnancies at risk for phenylketonuria. Archives of Disease in Childhood-Fetal and Neonatal Edition. 2019;104(1):F24–9.

28. Xu Y, Li X, Ge HJ, Xiao B, Zhang YY, Ying XM. Haplotype-based approach for noninvasive prenatal tests of Duchenne muscular dystrophy using cell-free fetal DNA in maternal plasma. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 2015;17(11):889–96. PMID: 25654318. Available from: https://doi.org/10.1038/gim.2014.207.

29. Mohan P, Lemoine J, Trotter C, Rakova I, Billings P, Peacock S, et al. Clinical experience with non-invasive prenatal screening for single-gene disorders. Ultrasound in Obstetrics & Gynecology : The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2022;59(1):33–9. PMID: 34358384. Available from: https://doi.org/10.1002/uog.23756.

30. Bauer M, Hutterer G, Eder M, Majer S, Leshane E, Johnson KL. A prospective analysis of cell-free fetal DNA concentration in maternal plasma as an indicator for adverse pregnancy outcome. Prenatal Diagnosis. 2006;26(9):831–6. PMID: 16832830. Available from: https://doi.org/10.1002/pd.1513.

31. Yuan X, Zhou L, Zhang B, Wang H, Jiang J, Yu B. Early second-trimester plasma cell free DNA levels with subsequent risk of

pregnancy complications. Clinical Biochemistry. 2019;71:46–51. PMID: 31278894. Available from: https://doi.org/10.1016/j.clinbiochem.2019.07.001.

32. Kumar N, Singh AK. Cell-Free Fetal DNA: A Novel Biomarker for Early Prediction of Pre-eclampsia and Other Obstetric Complications. Current Hypertension Reviews. 2019;15(1):57–63. PMID: 29766818. Available from: https://doi.org/10.2174/1573402114666180516131832.

33. Guo Z, Yang F, Zhang J, Zhang Z, Li K, Tian Q, et al. Whole-Genome Promoter Profiling of Plasma DNA Exhibits Diagnostic Value for Placenta-Origin Pregnancy Complications. Advanced Science. 2020;7(7):1901819. PMID: 32274292. Available from: https://doi.org/10.1002/advs.201901819.

34. Ashoor G, Syngelaki A, Poon LCY, et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound in Obstetrics & Gynecology. 2012;41(1):26–32. Available from: https://doi.org/10.1002/uog.12331.

35. Zhao Q, Chen J, Ren L, Zhang H, Liu D, Xi X, et al. Two cases of placental trisomy 21 mosaicism causing false-negative NIPT results. Molecular Cytogenetics. 2023;16(1):16. Available from: https://doi.org/10.1186/s13039-023-00643-3.

36. Hartwig TS, Ambye L, Werge L, Weiergang MK, Nørgaard P, Sørensen S, et al. Non-Invasive Prenatal Testing (NIPT) in pregnancies with trisomy 21, 18 and 13 performed in a public setting–factors of importance for correct interpretation of results. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2018;226:35–9. Available from: https://doi.org/10.1016/j.ejogrb.2018.04.042.

37. Wu WJ, Ma GC, Lee MH, Chen YC, Chen M. Normal prenatal ultrasound findings reflect outcome in case of trisomy 14 confined placental mosaicism developing after preimplantation genetic diagnosis. Ultrasound in Obstetrics & Gynecology : The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2017;50(1):128–30. PMID: 27790814. Available from: https://doi.org/10.1002/uog.17338.

38. Bianchi DW, Chudova D, Sehnert AJ, Bhatt S, Murray K, Prosen TL, et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies. Jama. 2015;314(2):162–9.

39. Kantor V, Mo L, DiNonno W, Howard K, Palsuledesai CC, Parmar S, et al. Positive predictive value of a single nucleotide polymorphism (SNP)-based NIPT for aneuploidy in twins: experience from clinical practice. Prenatal Diagnosis. 2022;42(13):1587–93. Available from: https://doi.org/10.1002/pd.6262.

40. Ngan OM, Yi H, Wong SY, Sahota D, Ahmed S. Obstetric professionals' perceptions of non-invasive prenatal testing for Down syndrome: clinical usefulness compared with existing tests and ethical implications. BMC pregnancy and childbirth. 2017;17:285. Available from: https://doi.org/10.1186/s12884-017-1474-6.